Selected research from leading health care experts whose findings have a direct bearing on public policies effecting medical progress. Research is chosen based on its quality and relevance by the Medical Progress Today editorial staff.

Selected Research

Imatinib Manipulation Modifies Resistant Leukemia
Medscape, 1-24-05

In the January 1 issue of Cancer, researchers reported that Gleevec resistant cancer cells, which over express the gene BCR-ABL, can be killed when Gleevec treatment is actually halted. “Abrupt withdrawal of the BCR-ABL inhibitor [Gleevec] from resistant leukemia cells leads to apoptosis of these BCR-ABL overexpressing cells.”

Ironically, Gleevec resistant cells were weakened by the discontinuation of Gleevec treatment; researchers theorize that this weakness “could be exploited” to make these cells more vulnerable to other forms of treatment.

Project FDA.
home   spotlight   commentary   research   events   news   about   contact   links   archives
Copyright Manhattan Institute for Policy Research
52 Vanderbilt Avenue
New York, NY 10017
(212) 599-7000